ToxNav germline genetic testing and PROMinet digital mobile application toxicity monitoring: Results of a prospective single‐center clinical utility study—PRECISE study

INTRODUCTION: In this study (PRECISE), we assess the clinical utility of a germline DNA sequencing‐based test (ToxNav) for mutations in DPYD and ENOSF1 genes to alter clinician‐prescribed fluoropyrimidine doses and the use of a digital application (PROMinet) to record patient‐reported chemotherapy t...

Descripción completa

Detalles Bibliográficos
Autores principales: Lee, Lennard Y. W., Starkey, Thomas, Sivakumar, Shivan, Fotheringham, Susan, Mozolowski, Guy, Shearwood, Vanessa, Palles, Claire, Camilleri, Philip, Church, David, Kerr, Rachel, Kerr, David
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2019
Materias:
Clinical Cancer Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6797583/
https://www.ncbi.nlm.nih.gov/pubmed/31486228
http://dx.doi.org/10.1002/cam4.2529

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6797583/
https://www.ncbi.nlm.nih.gov/pubmed/31486228
http://dx.doi.org/10.1002/cam4.2529

Ejemplares similares